Converting prescription drugs (Rx) to over-the-counter (OTC) products is complex yet achievable with the right expertise, offering faster, less costly regulatory processes. The U.S. Rx-to-OTC market, valued at $35 billion in 2021, is projected to reach $58 billion by 2031. This transition involves rigorous FDA regulations to ensure drugs are safe for self-diagnosis and use. Benefits include increased consumer access, reduced healthcare costs, and improved public health outcomes. Successful conversions require strategic planning, thorough consumer studies, and expert execution. Premier Research supports these conversions with specialized knowledge in regulatory strategies and clinical trials.

Join for free to read